Silence Therapeutics (SLN) Cost of Revenue (2024 - 2026)

Silence Therapeutics has reported Cost of Revenue for 3 years, with the latest figure at $11000.0 in Q1 2026.

• Quarterly Cost of Revenue fell 79.63% year-over-year to $11000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $172000.0 (down 98.1% YoY) and the FY2025 annual result came in at $215000.0, down 98.18% from the prior year.
• Cost of Revenue declined to $11000.0 in Q1 2026 per SLN's latest filing, from $12000.0 in the prior quarter.
• Over five years, Cost of Revenue peaked at $3.6 million in Q3 2024 and troughed at $11000.0 in Q1 2026.
• A 3-year average of $1.3 million and a median of $85000.0 in 2025 frame the typical range for Cost of Revenue.
• The sharpest annual moves came in 2025 and 2026: Cost of Revenue plunged 99.41% in 2025, then slumped 79.63% in 2026.
• Over 3 years, Cost of Revenue stood at $2.0 million in 2024, then slumped by 99.41% to $12000.0 in 2025, then fell by 8.33% to $11000.0 in 2026.
• According to Business Quant data, Cost of Revenue over the past three periods registered $11000.0, $12000.0, and $64000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.